Idarubicin

Idarubicin Brand Name– Idamycin PFS

What is Idarubicin

Idarubicin is an anthracycline chemotherapy agent indicated in combination with other approved antileukemic agents for the treatment of adults with acute myeloid leukemia including French-American-British classifications M1 through M7.

Cardiotoxicity and severe myelosuppression have been reported with idarubicin therapy; monitoring is recommended.

Indications

  1. acute lymphocytic leukemia (ALL)
  2. acute myelogenous leukemia (AML)
  3. acute promyelocytic leukemia
  4. chronic myelogenous leukemia (CML)
  5. non-Hodgkin’s lymphoma (NHL)

For the treatment of acute myelogenous leukemia (AML)

NOTE: Idarubicin has been designated an orphan drug by the FDA for the treatment of AML.

for remission induction therapy in AML, in combination with other approved antileukemic drugs including cytarabine

Side Effects

  1. abdominal pain
  2. alopecia
  3. anemia
  4. atrial fibrillation
  5. AV block
  6. bleeding
  7. bone marrow suppression
  8. bradycardia
  9. bullous rash
  10. cardiomyopathy
  11. cardiotoxicity
  12. chest pain (unspecified)
  13. diarrhea
  14. elevated hepatic enzymes
  15. enterocolitis
  16. fever
  17. GI perforation
  18. headache
  19. heart failure
  20. infection
  21. injection site reaction
  22. leukopenia
  23. myocardial infarction
  24. nausea
  25. nausea
  26. neutropenia
  27. oral ulceration
  28. oral ulceration
  29. pancytopenia
  30. peripheral neuropathy
  31. premature ventricular contractions (PVCs)
  32. QT prolongation
  33. radiation recall reaction
  34. rash
  35. seizures
  36. sinus tachycardia
  37. ST-T wave changes
  38. supraventricular tachycardia (SVT)
  39. thrombocytopenia
  40. tissue necrosis
  41. urticaria
  42. ventricular tachycardia
  43. vomiting
  44. vomiting

Monitoring Parameters

  • CBC
  • echocardiogram
  • LFTs
  • serum creatinine/BUN

Contraindications

  • accidental exposure
  • acute myocardial infarction
  • angina
  • anthracycline hypersensitivity
  • bone marrow suppression
  • breast-feeding
  • cardiac arrhythmias
  • cardiac disease
  • cardiotoxicity
  • children
  • dental disease
  • dental work
  • extravasation
  • heart failure
  • hepatic disease
  • herpes infection
  • hyperkalemia
  • hyperphosphatemia
  • hyperuricemia
  • hypocalcemia
  • infection
  • intramuscular administration
  • intramuscular injections
  • jaundice
  • maximum cumulative lifetime dose
  • neutropenia
  • ocular exposure
  • pregnancy
  • radiation therapy
  • renal impairment
  • requires a specialized care setting
  • requires an experienced clinician
  • subcutaneous administration
  • thrombocytopenia
  • tumor lysis syndrome (TLS)
  • vaccination
  • varicella
  • ventricular dysfunction
  • viral infection

Interactions

  • Cyclophosphamide
  • Gadobenate Dimeglumine
  • Palifermin
  • Penicillamine
  • Trastuzumab
  • Trastuzumab; Hyaluronidase
  • Tuberculin Purified Protein Derivative, PPD